Search

Wu Cheng Winston Shen

Supervisory Patent Examiner (ID: 7676, Phone: (571)272-3157 , Office: P/1628 )

Most Active Art Unit
1632
Art Unit(s)
1632, 1682, 1621, 1628, 1634
Total Applications
384
Issued Applications
62
Pending Applications
85
Abandoned Applications
246

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 16870421 [patent_doc_number] => 20210163888 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-03 [patent_title] => INDUCTION OF MYELINATING OLIGODENDROCYTES IN HUMAN CORTICAL SPHEROIDS [patent_app_type] => utility [patent_app_number] => 17/048289 [patent_app_country] => US [patent_app_date] => 2019-04-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10763 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17048289 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/048289
INDUCTION OF MYELINATING OLIGODENDROCYTES IN HUMAN CORTICAL SPHEROIDS Apr 15, 2019 Pending
Array ( [id] => 17674115 [patent_doc_number] => 20220187282 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-16 [patent_title] => CARDIOMYOCYTE PROLIFERATION [patent_app_type] => utility [patent_app_number] => 17/440081 [patent_app_country] => US [patent_app_date] => 2019-03-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35407 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17440081 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/440081
CARDIOMYOCYTE PROLIFERATION Mar 17, 2019 Pending
Array ( [id] => 16511550 [patent_doc_number] => 20200390807 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-17 [patent_title] => COMPOSITION AND METHOD FOR TARGETING NATURAL KILLER CELLS IN IMMUNOTHERAPY TO OVERCOME TUMOR SUPPRESSION WITH MANGANESE DIOXIDE NANOPARTICLES [patent_app_type] => utility [patent_app_number] => 16/971425 [patent_app_country] => US [patent_app_date] => 2019-02-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8947 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16971425 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/971425
COMPOSITION AND METHOD FOR TARGETING NATURAL KILLER CELLS IN IMMUNOTHERAPY TO OVERCOME TUMOR SUPPRESSION WITH MANGANESE DIOXIDE NANOPARTICLES Feb 19, 2019 Pending
Array ( [id] => 18003591 [patent_doc_number] => 20220362357 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-17 [patent_title] => Synergistic Combinations of Amino Acid Depletion Agent Sensitizers (AADAS) and Amino Acid Depletion Agents (AADA), and Therapeutic Methods of Use Thereof [patent_app_type] => utility [patent_app_number] => 17/271824 [patent_app_country] => US [patent_app_date] => 2018-12-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27614 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17271824 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/271824
Synergistic Combinations of Amino Acid Depletion Agent Sensitizers (AADAS) and Amino Acid Depletion Agents (AADA), and Therapeutic Methods of Use Thereof Dec 5, 2018 Abandoned
Array ( [id] => 17274748 [patent_doc_number] => 20210380946 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-09 [patent_title] => REDUCED INTENSITY CONDITIONING WITH MELPHALAN [patent_app_type] => utility [patent_app_number] => 17/289135 [patent_app_country] => US [patent_app_date] => 2018-11-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8221 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17289135 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/289135
REDUCED INTENSITY CONDITIONING WITH MELPHALAN Oct 31, 2018 Abandoned
Array ( [id] => 14930437 [patent_doc_number] => 20190300856 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-03 [patent_title] => Messenger RNA based expression of opsins and reporter proteins for electrophysiologic characterization of in vitro neurons and cardiomyocytes [patent_app_type] => utility [patent_app_number] => 15/998754 [patent_app_country] => US [patent_app_date] => 2018-08-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6958 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15998754 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/998754
Messenger RNA based expression of opsins and reporter proteins for electrophysiologic characterization of in vitro neurons and cardiomyocytes Aug 15, 2018 Abandoned
Array ( [id] => 17355378 [patent_doc_number] => 20220016174 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-20 [patent_title] => FOETAL MESENCHYMAL STEM CELL COMPOSITION OF ALLOGENIC ORGIN, TREATMENT METHOD AND USE THEREOF IN MASTITIS IN MILK-PRODUCING ANIMALS, INCLUDING CATTLE [patent_app_type] => utility [patent_app_number] => 17/251954 [patent_app_country] => US [patent_app_date] => 2018-06-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15119 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17251954 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/251954
FOETAL MESENCHYMAL STEM CELL COMPOSITION OF ALLOGENIC ORGIN, TREATMENT METHOD AND USE THEREOF IN MASTITIS IN MILK-PRODUCING ANIMALS, INCLUDING CATTLE Jun 14, 2018 Abandoned
Array ( [id] => 12178932 [patent_doc_number] => 20180037869 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-08 [patent_title] => 'CELL THERAPEUTIC AGENT FOR CANCER TREATMENT AND COMBINATION THERAPY WITH SAME' [patent_app_type] => utility [patent_app_number] => 15/554849 [patent_app_country] => US [patent_app_date] => 2016-03-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 12128 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15554849 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/554849
CELL THERAPEUTIC AGENT FOR CANCER TREATMENT AND COMBINATION THERAPY WITH SAME Mar 3, 2016 Abandoned
Menu